Low-dose aspirin for the prevention of atherothrombosis.
Carlo Patrono, Luis A García Rodríguez, Raffaele Landolfi...
https://pubmed.ncbi.nlm.nih.gov/16319386/Actively Recruiting
Led by Jilin University · Updated on 2026-10-01
2640
Participants Needed
1
Research Sites
4 weeks
Total Duration
Researchers are evaluating the effectiveness and safety of two different doses of aspirin 50 mg versus 100 mg once daily combined with a P2Y12 inhibitor in patients who have undergone successful percutaneous coronary intervention PCI and plan to receive at least 12 months of dual antiplatelet therapy. This randomized, open-label trial conducted in China aims to determine whether the lower aspirin dose is not worse than the standard dose in preventing major cardiac and cerebrovascular events, with a focus on Chinese patients. Participants are randomly assigned to receive either 50 mg or 100 mg of enteric-coated aspirin daily combined with a P2Y12 inhibitor, either ticagrelor or clopidogrel, based on clinical guidelines. All participants will continue this dual therapy for at least 12 months following PCI. The trial also includes a follow-up period with visits at 1, 6, and 12 months to assess outcomes and medication adherence. During the study, participants undergo clinical assessments and event verifications at the scheduled visits. Researchers will monitor the occurrence of major adverse cardiac and cerebrovascular events over 12 months, as well as clinically relevant bleeding events and net adverse clinical events. Safety data will be reviewed periodically by a monitoring committee. The total participation duration is 12 months post-randomization.
CONDITIONS
Aspirin 50mg vs 100mg Combined With P2Y12 Inhibitor After PCI
Q
Qian Tong, MD
M
Mingyou 'Zhang', MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Jilin University
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 12 months
Participants receive either low-dose (50 mg) or standard-dose (100 mg) aspirin daily combined with a P2Y12 inhibitor for at least 12 months following PCI.
Visits at 1 month, 6 months, and 12 months for clinical assessment and medication adherence evaluation
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Carlo Patrono, Luis A García Rodríguez, Raffaele Landolfi...
https://pubmed.ncbi.nlm.nih.gov/16319386/C Patrono, G Ciabattoni, P Patrignani...
https://pubmed.ncbi.nlm.nih.gov/3933848/Giovanni Davì, Carlo Patrono
https://pubmed.ncbi.nlm.nih.gov/18077812/Jilin University
Lead Sponsor